组间依西美坦研究长期随访结果
组间依西美坦研究纳入4724例绝经后早期乳腺癌患者,在2至3年他莫昔芬辅助内分泌治疗后随机继续他莫昔芬或换用依西美坦完成共5年治疗。中位随访120个月,雌激素受体阳性或状态未知人群中,依西美坦组乳腺癌无病生存事件508/2294(22.1%),他莫昔芬组603/2305(26.2%),10年绝对差异4.0%(95%CI 1.2%至6.7%),HR 0.81(95%CI 0.72至0.92) favoring exemestane。
要点
- 他莫昔芬治疗2至3年后换用依西美坦可持续降低乳腺癌复发风险,HR 0.81(95%CI 0.72至0.92)。
- 雌激素受体阳性或未知人群中10年乳腺癌无病生存绝对差异为4.0%(95%CI 1.2%至6.7%)。
- 总生存改善未达统计学显著,HR 0.89(95%CI 0.78至1.01;P=0.08)。
核心结论
- 他莫昔芬治疗2至3年后换用芳香化酶抑制剂策略可带来降低疾病复发和乳腺癌死亡率的持续获益。
研究设计与样本
- 组间依西美坦研究为研究者主导的研究,纳入4724例绝经后早期乳腺癌患者(临床试验信息:ISRCTN11883920)。
- 患者在2至3年他莫昔芬辅助内分泌治疗后无病生存者随机分配至继续他莫昔芬或换用依西美坦,完成共5年辅助内分泌治疗。
- 主要生存终点为乳腺癌无病生存(BCFS),分析聚焦雌激素受体阳性或状态未知人群(n=4599)。
主要发现
- 数据快照时中位随访120个月。
- 雌激素受体阳性或状态未知人群中,依西美坦组508/2294例(22.1%)发生BCFS事件,他莫昔芬组603/2305例(26.2%)。
- 依西美坦与他莫昔芬10年绝对差异为4.0%(95%CI 1.2%至6.7%),HR 0.81(95%CI 0.72至0.92) favoring exemestane。
- 多变量分析调整淋巴结状态、既往激素替代治疗和既往化疗后差异仍存在(HR 0.80;95%CI 0.71至0.90;P<0.001)。
- 雌激素受体阳性或状态未知人群10年总生存绝对差异为2.1%(95%CI -0.5%至4.6%),HR 0.89(95%CI 0.78至1.01;P=0.08);意向治疗人群绝对差异1.6%(95%CI -0.9%至4.1%),HR 0.91(95%CI 0.80至1.03;P=0.15)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane was associated with clinically relevant improvements in efficacy. Here, we report the final efficacy analyses of this cohort. Patients and Methods Patients who remained disease free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete a total of 5 years of adjuvant endocrine therapy. Given the large number of non-breast cancer-related deaths now reported, breast cancer-free survival (BCFS), with censorship of intercurrent deaths, was the primary survival end point of interest. Analyses focus on patients with estrogen receptor-positive or unknown tumors (n = 4,599). Results At the time of the data snapshot, median follow-up was 120 months. In the population that was estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were observed with 508 (22.1%) of 2,294 patients in the exemestane group and 603 (26.2%) of 2,305 patients in the tamoxifen group. The data corresponded to an absolute difference (between exemestane and tamoxifen) at 10 years of 4.0% (95% CI, 1.2% to 6.7%), and the hazard ratio (HR) of 0.81 (95% CI, 0.72 to 0.92) favored exemestane. This difference remained in multivariable analysis that was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR, 0.80; 95% CI, 0.71 to 0.90; P < .001). A modest improvement in overall survival was seen with exemestane; the absolute difference (between exemestane and tamoxifen) at 10 years in the population that was estrogen receptor positive or had unknown estrogen receptor status was 2.1% (95% CI, -0.5% to 4.6%), and the HR was 0.89 (95% CI, 0.78 to 1.01; P = .08). For the intention-to-treat population, the absolute difference was 1.6% (95% CI, -0.9% to 4.1%); the HR was 0.91 (95% CI, 0.80 to 1.03, P = .15). No statistically significant difference was observed in the proportion of patients who reported a fracture event in the post-treatment period. Conclusion The Intergroup Exemestane Study and contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2 to 3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.
引用
- Morden JP, Alvarez I, Bertelli G, et al. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol. 2017. PMID: 28467729. doi:10.1200/JCO.2016.70.5640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。